apus: the income statement

MyFinsight

Apimeds Pharmaceuticals US, Inc. (APUS)

For the quarter ending 2025-06-30, APUS made $5,729 in revenue. -$2,662,193 in net income. Net profit margin of -46468.72%.

Unit: Dollar

	2025-06-30
Research and development expenses	651,784
General and administrative expenses	2,012,120
Total operating expenses	2,663,904
Loss from operations	-2,663,904
Interest income	15,247
Interest expense	23,054
Change in fv of warrant liability	-9,518
Other income (expense)	1,711
Net loss	-2,662,193

Net loss per common share - basic (in dollars per share)	-0.26
Net loss per common share - diluted (in dollars per share)	-0.26
Weighted average common shares outstanding - basic (in shares)	10,369,127
Weighted average common shares outstanding - diluted (in shares)	10,369,127

Unit: Dollar